Company

Elpiscience Biopharma

As of the edition of 20 October 2026, Elpiscience Biopharma runs 5 drugs; it is on route A at 2 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

The records place 2 company names in this family.

Drugs by status

StatusCount
Active2
Stopped1
Status not established2
Total5

Where it needs a new molecule

Route A at 2 targets, route B at 0 targets.

Three of its 2 rows, by target and route
TargetRoute
CD274 Programmed cell death 1 ligand 1Route A
TNFRSF9 Tumor necrosis factor receptor superfamily member 9Route A

All 2 rows on route A or B

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Cancer: 4 trials led
  • Lungs and airways: 1 trials led